BioSyntech, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BSYI research report →
Companybiosyntech.com
BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration.
- CEO
- Amine Selmani
- IPO
- 2000
- HQ
- Laval, QC, CA
Price Chart
Valuation
- Market Cap
- $229.03K
- P/E
- -0.00
- P/S
- 7.73
- P/B
- -0.00
- EV/EBITDA
- -0.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 60.82%
- Op Margin
- -27056.25%
- Net Margin
- -31739.11%
- ROE
- 517.27%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $40.77K · -85.12%
- Net Income
- $-12,938,767 · -39.59%
- EPS
- $-0.13 · -30.00%
- Op Income
- $-11,029,752
- FCF YoY
- -15.29%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.15
- Avg Volume
- 221
Get TickerSpark's AI analysis on BSYI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BSYI Coverage
We haven't published any research on BSYI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BSYI Report →